Childress Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Childress Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Sell	523 -44	-8%	-$29.9K	0.05%	257
2026 Q1	$438K	Buy	567 +158	+39%	+$121K	0.08%	177
2025 Q4	$316K	Buy	+409	New	+$278K	0.05%	267
2024 Q4	–	Sell	-271	Closed	-$285K	–	231
2024 Q3	$285K	Sell	271 -1	-0.4%	-$1.11K	0.08%	173
2024 Q2	$286K	Sell	272 -7	-3%	-$6.79K	0.08%	158
2024 Q1	$269K	Sell	279 -111	-28%	-$106K	0.08%	159
2023 Q4	$343K	Buy	390 +28	+8%	+$23.1K	0.1%	123
2023 Q3	$298K	Buy	+362	New	+$285K	0.1%	127
2023 Q1	–	Sell	-332	Closed	-$240K	–	153
2022 Q4	$240K	Buy	332 +4	+1%	+$2.95K	0.08%	155
2022 Q3	$234K	Buy	+328	New	+$206K	0.09%	145
2021 Q1	–	Sell	-63	Closed	-$29K	–	768
2020 Q4	$29K	Buy	+63	New	+$34K	0.02%	287

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Childress Capital Advisors's REGN Position: Q2 2026 in Review

Childress Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 7.8% in Q2 2026, selling an estimated $29.9K and leaving 523 shares worth $326K. The position accounts for 0.05% of the portfolio, ranked #257.

Childress Capital Advisors first reported a position in REGN in Q4 2020 and has held it in 11 quarters since. The position peaked at $438K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Childress Capital Advisors held 523 shares of Regeneron Pharmaceuticals worth $326K as of Q2 2026.
Childress Capital Advisors sold 44 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $29.9K.
Regeneron Pharmaceuticals made up 0.05% of Childress Capital Advisors's portfolio in Q2 2026, its #257 holding.
Childress Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
Childress Capital Advisors's Regeneron Pharmaceuticals position peaked at $438K in Q1 2026.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Childress Capital Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.